QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Aflibercept Biosimilar, VEGF-Trap Biology, Retinal Disease and Product Pharmacovigilance

Test your understanding of the concepts covered by Aflibercept Biosimilar: VEGF-Trap Biology, Retinal Disease, Biosimilarity and Product Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which finding most strongly supports an acute volume-related intraocular pressure mechanism after injection?

Visual blurring beginning immediately, with IOP of 48 mmHg that falls after treatment Gradual retinal haemorrhage months after treatment with normal IOP Delayed fever and hypopyon with positive vitreous culture Bilateral myocardial infarction after repeated injections

Question 2 of 10 Why is the treated eye an important field in an intravitreal adverse-event report?

The eye laterality has no effect on causal interpretation An event confined to the injected eye may support a different causal model from an event in the untreated fellow eye Only the right eye can receive aflibercept Laterality is needed only for billing purposes

Question 3 of 10 Why should endophthalmitis, sterile intraocular inflammation and retinal vasculitis not be pooled into a single generic 'eye inflammation' category during signal review?

They have different likely mechanisms, diagnostic criteria and control measures They always occur in different patient populations Pooling is required for all biological medicines They are administrative terms with no clinical significance

Question 4 of 10 Which set of information would be most valuable for assessing a reported myocardial infarction after intravitreal treatment?

Only the product's generic name Baseline cardiovascular disease, timing relative to injection, antithrombotic therapy and other VEGF-inhibitor exposure Only the patient's visual acuity before injection The colour and packaging design of the syringe

Question 5 of 10 What is the primary regulatory rationale for extrapolating a biosimilar's use to multiple reference-product indications?

All retinal diseases are clinically identical A single clinical trial automatically proves efficacy in every disease Strong analytical, functional and mechanistic similarity can reduce the need to repeat large efficacy trials in every indication Extrapolation means that no evidence exists for the biosimilar

Question 6 of 10 A patient reports visual loss after a first Pavblu injection following two years of reference aflibercept. Which conclusion is most professionally justified at the initial assessment stage?

The switch caused the event because it occurred after the switch The biosimilar cannot be involved because biosimilarity was established The event requires assessment of disease activity, procedure-related risks, objective findings, product identity and alternative causes The report should be dismissed as a nocebo effect

Question 7 of 10 A patient develops severe pain and visual loss three days after an intravitreal injection. Which initial PV approach is most appropriate?

Classify the event immediately as sterile inflammation based only on timing Classify it immediately as endophthalmitis because all painful post-injection events are infectious Obtain examination findings, cultures, imaging and treatment information to distinguish infectious from sterile inflammation Record only the patient's visual acuity because the diagnosis is clinically unimportant

Question 8 of 10 Which statement best explains why pharmacovigilance of a biosimilar must preserve both class knowledge and product identity?

Biosimilarity means that product-level surveillance is unnecessary Expected shared clinical effects support class-based interpretation, while brand and batch data are needed to detect product or lot-specific issues Product identity matters only before marketing authorisation Class knowledge and product identity are mutually exclusive approaches

Question 9 of 10 What is the most accurate distinction between a biosimilar and a conventional small-molecule generic?

A biosimilar must be molecularly identical in every measurable attribute A biosimilar is evaluated through comparative evidence because biological products may have controlled structural variability A biosimilar does not require clinical or immunogenicity assessment A generic is always more complex to manufacture than a biological medicine

Question 10 of 10 A patient with neovascular AMD develops a new haemorrhagic lesion beneath the macula. Which disease mechanism is most relevant?

Pathological choroidal neovascularisation with leakage from fragile abnormal vessels Acute volume-related elevation of intraocular pressure A procedure-related retinal tear caused by the injection needle Systemic inhibition of platelet production by aflibercept

QPPV.com

Knowledge Assessment: Aflibercept Biosimilar, VEGF-Trap Biology, Retinal Disease and Product Pharmacovigilance

Cookie Settings